This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Buy the Dip With These ETFs Under $20
by Sweta Killa
The recent market rout led by the tech selloff has provided investors a great opportunity to tap the stocks under $20.
ETFs Under $20 From 5 Hottest Zones
by Sweta Killa
Let us dig into some of the ETFs that are below $20 and are from the hottest areas currently. These low-priced ETFs could lead to huge gains in the coming months.
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Genomics ETF (GNOM) Hits New 52-Week High
by Sanghamitra Saha
The ETF GNOM hit a 52-week high on May 22. Can it rally further?
Profit from the Genomics Market Momentum With These ETFs
by Sweta Jaiswal, FRM
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
4 Sector ETFs That Beat the Market in Q4
by Sanghamitra Saha
While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.
Beyond Biotech, 5 ETFs Up At Least 10% in Q4
by Sanghamitra Saha
Apart from biotech, these ETFs are seeing solid momentum in the ongoing quarter.
Biotech Tops in November: Best ETFs & Stocks
by Sweta Killa
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Genomics ETFs Surge on CRISPR's Gene Editing Progress
by Sweta Jaiswal, FRM
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.